(Q37792340)

23 August 2017

title

Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects (English)

1 reference

23 August 2017

Kazuo Maruyama

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

28 October 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0169409X1000181X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

https://api.elsevier.com/content/article/PII:S0169409X1000181X?httpAccept=text/plain

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Advanced Drug Delivery Reviews

20 July 2024

published in

1 reference

23 August 2017

volume

63

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

161-169

1 reference

Pharmacokinetics of stealth versus conventional liposomes: effect of dose

23 August 2017

cites work

4

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Cardiac safety of liposomal anthracyclines

20 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

The reticuloendothelial system and bloodstream clearance

20 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages

20 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol)

20 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes

20 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Transport of molecules across tumor vasculature

20 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules

20 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

20 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo.

20 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

20 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Liposomes for the sustained drug release in vivo

20 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo

20 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol)

20 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol).

20 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo

20 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome

20 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells

20 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy

20 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size

20 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy

20 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Future directions of liposome- and immunoliposome-based cancer therapeutics

20 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Liposomal encapsulated anti-cancer drugs

20 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles

20 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer

20 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

20 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

20 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Cardiac safety of liposomal anthracyclines

20 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Pros and cons of the liposome platform in cancer drug targeting

20 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Liposomal drug formulations. Rationale for development and what we can expect for the future

20 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Possibility of active targeting to tumor tissues with liposomes

20 July 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo

20 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages

20 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Characterization of in vivo immunoliposome targeting to pulmonary endothelium

20 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Improvement of therapeutic effect by using Fab' fragment in the treatment of carcinoembryonic antigen-positive human solid tumors with adriamycin-entrapped immunoliposomes.

20 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies

20 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo

20 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes

20 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

The transferrin receptor: its diagnostic value and its potential as therapeutic target

20 July 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Transferrin receptor in oral tumors

20 July 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice

20 July 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).

20 July 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Boron neutron capture therapy for cancer. Realities and prospects.

20 July 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome

20 July 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.

20 July 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Passive and active drug targeting: drug delivery to tumors as an example

20 July 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

20 July 2024

Identifiers

1 reference

23 August 2017

1 reference